Alkhouri, Naim

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 2,084

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 802

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 801

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 528

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research

Cited by 522

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

Davison, B. A., Harrison, S. A., Cotter, G., Alkhouri, N., Sanyal, A., Edwards, C., Colca, J. R., Iwashita, J., Koch, G. G., & Dittrich, H. C. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentReliability and Agreement in Measurement

Cited by 448

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Harrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023) · Nature Medicine

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 435

Association of Bariatric Surgery with Major Adverse Liver and Cardiovascular Outcomes in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis

Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA

Bariatric Surgery and OutcomesLiver Disease Diagnosis and Treatment

Cited by 375

Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension

Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 358

Challenges and opportunities in NASH drug development

Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 353

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Loomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 296

Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

Harrison, S. A., Gawrieh, S., Roberts, K., Lisanti, C. J., Schwope, R. B., Cebe, K. M., Paradis, V., Bedossa, P., Aldridge Whitehead, J. M., Labourdette, A., et al. (2021) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 293

Therapeutic pipeline in nonalcoholic steatohepatitis

Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 278

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W., Romero‐Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., et al. (2019) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 277

Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease

Alkhouri, N., Morris‐Stiff, G., Campbell, C., Lopez, R., Tamimi, T. A., Yerian, L., Zein, N. N., & Feldstein, A. E. (2012) · Liver International

Liver Disease Diagnosis and TreatmentInflammatory Biomarkers in Disease Prognosis

Cited by 256

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 230

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 217

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study

Harrison, S. A., Alkhouri, N., Davison, B. A., Sanyal, A., Edwards, C., Colca, J. R., Lee, B. H., Loomba, R., Cusi, K., Kolterman, O., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 211

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Harrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Pablo Frias, J., Taub, R., & Alkhouri, N. (2021) · Hepatology Communications

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 197

Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis

Younossi, Z. M., Zelber-Sagi, S., Lazarus, J. V., Wong, V. W.-S., Yilmaz, Y., Duseja, A., Eguchi, Y., Castera, L., Pessoa, M. G., Oliveira, C. P., et al. (2025) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 194

Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study

Anstee, Q. M., Neuschwander-Tetri, B. A., Wai-Sun Wong, V., Abdelmalek, M. F., Rodriguez-Araujo, G., Landgren, H., Park, G. S., Bedossa, P., Alkhouri, N., Tacke, F., et al. (2024) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 179

Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis

Mohamad, B., Shah, V., Onyshchenko, M., Elshamy, M., Aucejo, F., Lopez, R., Hanouneh, I. A., Alhaddad, R., & Alkhouri, N. (2016) · Hepatology International

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and Treatment

Cited by 166

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

Alkhouri, N., Lawitz, E., Noureddin, M., DeFronzo, R., & Shulman, G. I. (2020) · Expert Opinion on Investigational Drugs

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 162

Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis

Noureddin, M., Jones, C., Alkhouri, N., Gomez, E. V., Dieterich, D. T., Rinella, M. E., Therapondos, G., Girgrah, N., Mantry, P. S., Sussman, N. L., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 140